XERS achieved a dramatic turnaround from significant losses to profitability, with operating income swinging from -$33.6M to +$24.9M and revenue more than doubling to $49.6M.
This represents a fundamental transformation from a loss-making biotech to a profitable commercial-stage company, suggesting their marketed products (Recorlev, Gvoke, Keveyis) are gaining significant commercial traction. The company has moved from negative stockholders equity to positive $13.7M, indicating improved financial stability, though rising interest expense of 73.6% suggests increased debt financing during this growth phase.
XERS delivered exceptional financial performance with revenue surging 143% to $49.6M and achieving profitability with $554K net income versus prior year's -$54.8M loss. The company strengthened its balance sheet significantly, moving from negative equity to positive $13.7M while building cash reserves to $111M and expanding inventory by 43% to support growing demand. However, interest expense nearly doubled to $26.6M, indicating the company relied heavily on debt financing to fund this growth trajectory, though the overall financial transformation suggests a successful transition to sustainable commercial operations.
Capital expenditure jumped 187.8% — major investment cycle underway; assess returns on deployment.
Operating cash flow surged 177.4% — exceptional cash generation, highest quality earnings signal.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Equity base grew 146.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Strong top-line growth of 142.7% — accelerating demand or successful expansion into new markets.
Net income grew 101% — bottom-line growth signals improving overall business health.
Interest expense surged 73.6% — significant debt increase or rising rates materially impacting earnings.
Cash position surged 55% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 43.3% — improving short-term liquidity or inventory/receivables build.
Inventory surged 42.5% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →